Evidence map›Paper›PMID 42611536›Full record

ReviewESC heart failure2026

Device therapies in cardiorenal syndrome: an expert review.

Jeroen Dauw, Guillaume Baudry, Marta Cobo Marcos, Mateusz Guzik, Juan Carlos Lopez, Biykem Bozkurt, Gracjan Iwanek, Masatake Kobayashi, Òscar Miró, Peder Langeland Myhre and 6 more

Abstract readReview
In one paragraph

Review in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jeroen DauwCardiovascular Center Aalst, AZORG Hospital, Moorselbaan 164, Aalst 9300, Belgium.ORCID 0000-0003-4605-3450
Guillaume BaudryINSERM, Centre Investigations Cliniques 1433, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Université de Lorraine, CHRU de Nancy, Nancy, France.ORCID 0000-0002-9200-2729
Marta Cobo MarcosCardiology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Mateusz GuzikDepartment of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0001-9711-6568
Juan Carlos LopezCardiology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Biykem BozkurtCardiology Section, Winters Center for Heart Failure, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-6362-0253
Gracjan IwanekDepartment of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0002-8574-9963
Masatake KobayashiDepartment of Cardiology, Tokyo Medical University, Tokyo, Japan.
Òscar MiróEmergency Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-7924-9751
Peder Langeland MyhreDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Alberto PalazzuoliCardiovascular Diseases Unit, Cardio Thoracic and Vascular Department, S. Maria Alle Scotte Hospital, University of Siena, Siena, Italy.ORCID 0000-0002-6235-984X
Jeffrey M TestaniSection of Cardiovascular Medicine, Yale University, New Haven, CT, USA.
Marco MetraDepartment of Cardiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy.
Piotr PonikowskiDepartment of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Wilfried MullensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.ORCID 0000-0001-9995-8590
Jan BiegusDepartment of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0001-9977-7722

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing cardiorenal syndrome in acute decompensated heart failure remains a major challenge in contemporary cardiology. While pharmacological decongestion with diuretics is the cornerstone of therapy and is effective in most patients, worsening renal function and diuretic resistance continue to pose challenges in selected cases. Device-based therapies are increasingly explored to target key pathophysiological mechanisms underlying cardiorenal dysfunction. This expert review builds on a conceptual framework for device-based therapies. Rather than cataloguing individual technologies, we apply a functional framework that classifies devices according to their primary mode of action: reduction of venous or lymphatic congestion ('pullers'), augmentation of arterial perfusion ('pushers'), and direct removal of sodium and/or fluid ('removers'). For each category, we integrate pathophysiological rationale with available clinical evidence, highlighting the predominance of early-phase physiological evidence and the need for randomized studies demonstrating benefit beyond optimized contemporary medical care.

Indexed as

Cardio-Renal SyndromeHeart FailureHumansAcute heart failureCardiorenal syndromeDecongestionDevice therapyDiuretic resistance

Identifiers

PMID42611536
PMCPMC13483987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.